TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06644573
Drug: Diprivan (propofol), Astra-Zeneca
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diprivan/Propofol is a short-acting intravenous anesthetic used in PROSOMNIA Sleep Therapy to induce rapid and controlled REM sleep. Unlike other sleep aids, Propofol works by potentiating GABA_A receptor activity, leading to a deeper and faster transition into sleep. The administration is closely monitored in real-time using EEG to ensure optimal sleep stages are achieved. Propofol is distinct from traditional sedatives due to its precise control, rapid onset, and ability to clear adenosine from the brain, reducing sleep pressure effectively and safely.
Study: NCT04339270
Drug: Azithromycin according to rheology or symptoms
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Treatment according to standard COPD management, except for the prescription of azithromycin, which will be prescribed in function of mucus rheology or as a function of sputum complaints (here defined by a CASA-Q sputum symptoms score \<70).~The rheology of mucus will be quantified every 3 months.~* If the patient has spontaneous or induced sputum, and this sputum has a critical constraint (tau-C) \> 39, a prescription for 3 months of azithromycin treatment will be initiated. This prescription may be renewed every 3 months during the 12 months of follow-up planned in this study.~* If the patient has a sputum symptoms score \<70, a prescription for 3 months of azithromycin treatment will be initiated. This prescription can be renewed every 3 months during the 12 months of follow-up planned in this study, if the patient continues to obtain a sputum symptoms score \<70.~* If the patient has a sputum symptoms score\> 70, management is not changed.
Study: NCT06275204
Drug: Standard triple therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants who are positive for H. pylori will receive a standard triple therapy:~Antibiotic 1 - Amoxicillin 2 x 1000 mg, Antibiotic 2 - Clarithromycin 2 x 500 mg, Proton pump inhibitor - Esomeprazole 2 x 40 mg.
Study: NCT06726148
Drug: ECI830
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental
Study: NCT04969731
Drug: Immuncell-LC
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV
Study: NCT00261560
Drug: acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06726369
Drug: MK-6204 (SKB535) for Injection
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-6204 (SKB535) for injection is administered every 3 weeks (q3w) until radiographic disease progression (PD), intolerable toxicity, death, or discontinuation of treatment, whichever occurs first.
Study: NCT06726850
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the placebo arm, participants will consume a placebo matching GenSci1-144 for 12 consecutive weeks.
Study: NCT06726850
Drug: GS1-144
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the GS1-144 arm, participants will receive multiple doses of GS1-144 tablets for 12 consecutive weeks
Study: NCT06427447
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (gemcitabine plus capecitabine)
Study: NCT06439563
Drug: JP-1366 10 mg
Normalized name: ALCOHOL 70 mL in 100 mL TOPICAL GEL [JP P Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: JP-1366 10 mg, tablet, orally once a day for up to 24 weeks
Study: NCT06439563
Drug: Lanston Capsule 15 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanston Capsule 15 mg orally once a day for up to 24 weeks
Study: NCT06439563
Drug: JP-1366 10 mg placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: JP-1366 10 mg placebo, tablet, orally once a day for up to 24 weeks
Study: NCT06439563
Drug: Lanston Capsule 15 mg placebo
Normalized name: PLACEBO CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanston Capsule 15 mg placebo, orally once a day for up to 24 weeks
Study: NCT06578585
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection/infusion
Study: NCT06798207
Drug: TQB2102 for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC).
Study: NCT06721949
Drug: Taurine
Normalized name: Taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Taurine is a naturally occurring amino sulfonic acid commonly found in the body. It is marketed as a natural health product/supplement and plays an important role in the body.
Study: NCT06721949
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo capsule is visually identical to the taurine capsule.
Study: NCT05016895
Drug: Single-dose azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bi-annual mass, community-based distribution of single-dose azithromycin to children ages 1 to 11 months.
Study: NCT06729021
Drug: LMWH
Normalized name: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin may be used after procedure by the decision of the doctor
Study: NCT06716203
Drug: Drug: 5 mg BGM0504 Administered SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: BGM0504 Administered SC
Study: NCT06716203
Drug: Drug: : 10 mg BGM0504 Administered SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: BGM0504 Administered SC
Study: NCT06716203
Drug: Drug: Placebo Administered SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Placebo Administered SC
Study: NCT06709820
Drug: LY4060874
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06709820
Drug: LY4060874
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT06709820
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06709820
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT06733129
Drug: direct IV injection
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: direct IV injection at dosage of 2 mg/kg (adjusted body weight if BMI \> 30) after completing pre-oxygenation
Study: NCT06722235
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mezagitamab placebo-matching injection administered SC.
Study: NCT06721494
Drug: Sterile Saline
Normalized name: Aqua Care Sterile Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile Saline for intravenous administration
Study: NCT06721494
Drug: CS-1103
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS-1103 for intravenous administration
Study: NCT06727864
Drug: 4-month regimen (2HERZ/2HRE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-month (2HERZ/2HRE)
Study: NCT06727604
Drug: IMVT-1402
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg SC QW for 52 weeks
Study: NCT06727604
Drug: IMVT-1402
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg SC QW for 26 weeks followed by Placebo SC QW for 26 weeks
Study: NCT06727604
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC QW for 52 weeks
Study: NCT06727734
Drug: Piroxicam
Normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Piroxicam 40 mg
Study: NCT06727734
Drug: Placebo - LNG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of levonorgestrel
Study: NCT06727734
Drug: Placebo - Piroxicam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of piroxicam
Study: NCT06727734
Drug: Placebo - UPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of ulipristal acetate
Study: NCT05355441
Drug: Ibuprofen 600 mg
Normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Routine clinical practice treatments recommended by the medical team involved
Study: NCT06722586
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo two pills per day
Study: NCT06731192
Drug: Placebo control drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group of patients received a total of 2 intravenous infusions of normal saline (the same volume, specifications and batches used in the experimental group) as a placebo control during the treatment period on the basis of conventional symptomatic and supportive treatment. The interval between the two infusions was 14 days.~Conventional clinical treatment refers to symptomatic treatment with ACEI and ARB drugs.
Study: NCT06731868
Drug: LPM3770164 sustained release tablet 5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPM3770164 sustained release tablet once daily oral dosage at 5 mg for 6 weeks
Study: NCT06731868
Drug: LPM3770164 sustained release tablet 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPM3770164 sustained release tablet once daily oral dosage at 10 mg for 6 weeks.
Study: NCT06731868
Drug: LPM3770164 sustained release tablet 20 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPM3770164 sustained release tablet once daily oral dosage at 20 mg for 6 weeks.
Study: NCT06731868
Drug: LPM3770164 sustained release tablet simulant
Normalized name: STAPHYLOCOCCUS SIMULANS
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPM3770164 sustained release tablet simulant once daily oral for 6 weeks.
Study: NCT06731478
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: For Arms M1 and E1: 5-FU or capecitabine will be administered.~For Arms M2 and E2: Cisplatin plus 5-FU or oxaliplatin plus capecitabine will administered.
Study: NCT06730542
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive Methotrexate as per standard of care (SOC).
Study: NCT06730542
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive Cyclophosphamide as per standard of care (SOC), as part of combination standard of care Pola-R-CHP therapy.
Study: NCT06730542
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive Doxorubicin as per standard of care (SOC), as part of combination standard of care Pola-R-CHP therapy.
Study: NCT06592261
Drug: Insulin regular, 2.0-3.2 mU/m2/min (euinsulinemia)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion to recapitulate euinsulinemia (normal basal insulin)
Study: NCT06735079
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo serves as a control to evaluate the effectiveness and safety of REL-1017. It is an inactive substance that matches the active drug in appearance but contains no active ingredients. The placebo group allows researchers to compare outcomes, such as changes in depressive symptoms, with the active drug group.~The double-blind design ensures neither participants nor researchers know who is receiving the active treatment or placebo, eliminating bias. The placebo also helps assess whether observed side effects are due to the drug or unrelated factors.~Participants are randomly assigned to receive either REL-1017 or the placebo, both administered once daily for 28 days. This helps establish REL-1017's clinical effectiveness and safety in treating Major Depressive Disorder (MDD).
Study: NCT06735235
Drug: 250 ppm F as MFP
Normalized name: F
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
Study: NCT06735235
Drug: 1100 ppm as MFP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
Study: NCT06735235
Drug: 2800 ppm F as MFP
Normalized name: F
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
Study: NCT06732388
Drug: Placebo Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT06733298
Drug: [ 14C]-labeled RO7269162
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive one oral dose of \[14C\]-labeled RO7269162.
Study: NCT06741072
Drug: Dulbecco''s Phosphate-Buffered Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given SC
Study: NCT06737549
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 2ml volume of physiological saline (PS) injected intramuscularly into the gluteal muscle, three times a week for 6 weeks.
Study: NCT05281523
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as normal saline using a pre-filled syringe.
Study: NCT04629547
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be taken nightly for 24 months.
Study: NCT04944524
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1. Methotrexate (15 mg/week initially and progressively increased every week by 2.5 mg, to a maximum and optimal dose of 20 mg/week)~2. Basic treatment with prednisone. (1) the initial dose of prednisone (or equivalent): 0.8mg/kg/day. (2) Glucocorticoids tapering: after two weeks' usage of initial glucocorticoids dose, glucocorticoids can be tapered if there's no disease activity (BVAS/WG=0) or at least 50% reduction of BVAS/WG and no new manifestations. Prednisone (or equivalent) was reduced to 10mg/d at the time of randomization.
Study: NCT05047952
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo pill will be taken once daily.
Study: NCT05903859
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in this group will receive a placebo pill by mouth twice a day for a total of 90 days.
Study: NCT06736327
Drug: SKB500
Approvals — FDA: no, EMA: no, PMDA: no
Description: The administration route of SKB500 is intravenous infusion, with a dosing frequency of Q3W.
Study: NCT06745388
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receives no additional medication or infusion
Study: NCT05690334
Drug: Crystalloid - 0 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: No fluid coload was given. An initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
Study: NCT05690334
Drug: Crystalloid - 5 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml/kg crystalloid coload combined with an initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
Study: NCT05690334
Drug: Crystalloid - 10 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml/kg crystalloid coload combined with an initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
Study: NCT06743867
Drug: Pressurized Intraperitoneal Aerosol Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: The comprehensive therapeutic strategy will be modified based on the integrated 2- or 3-week systemic chemotherapies. In the interim, a total of three PIPAC procedures will be conducted for all qualifying patients.~1. PIPAC combined with 2-week systemic chemotherapies:~   PIPAC therapy will occur every four weeks, while systemic chemotherapies will be administered during the first and third weeks following the initial and second PIPAC procedures respectively.~2. PIPAC combined with 3-week systemic chemotherapies:~(1) Scheme 1: PIPAC therapy will occur every 6 weeks, with systemic chemotherapies administered during the 1st and 4th weeks following the first and second PIPAC procedures, respectively.~(2) Scheme 2: PIPAC therapy will occur every 6 weeks, while systemic chemotherapies will be administered in the 2nd and 5th weeks following the initial and second PIPAC procedures, respectively.
Study: NCT06745518
Drug: TS-172
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration of TS-172 20\~60 mg/day
Study: NCT06745518
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration of placebo
Study: NCT04786548
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive standardized pharmacotherapy with celecoxib 100mg twice daily for the first week, and will then, if well-tolerated, will be increased to 200mg twice daily for the next seven weeks.
Study: NCT05097248
Drug: Liposomal Doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal Doxorubicin 40 mg/m2 on D1 every 3 weeks; 6 cycles are planned to be completed or discontinued due to intolerable toxicity or progression.
Study: NCT06731101
Drug: Anticholinergic and Antidepressant Drugs
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tryptizole Librax
Study: NCT06731270
Drug: Diclofenac Potassium
Normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT06731556
Drug: Intranasal Diclofenac Sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium at a concentration of 0.0625 mg/mL was administered intranasally.
Study: NCT06731556
Drug: Intranasal Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen at a concentration of 0.375 mg/mL was administered intranasally.
Study: NCT06731023
Drug: Other antibiotics
Normalized name: Other antibiotics for topical use
Approvals — FDA: no, EMA: no, PMDA: no
Description: The selection of other antibiotics is based on the results of drug susceptibility testing.
Study: NCT06730373
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m² Q3W
Study: NCT06731075
Drug: ORMD-0801 8 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 8 mg capsule between 8 PM to 12 Midnight and no sooner than 1 hour after dinner and 2 placebo capsules (1 in the morning and 1 at night).
Study: NCT06731075
Drug: ORMD-0801 16 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 8 mg capsules between 8 PM to 12 Midnight and no sooner than 1 hour after dinner and 1 placebo capsule in the morning.
Study: NCT06731647
Drug: KETOPROFEN(RP19583)
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: one intravenous dose of ketoprofen 100 mg followed by 5 doses every 12 h of ketoprofen LP 100 mg (a total regimen of 6 doses of ketoprofen every 12 h for 72h)
Study: NCT06731647
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo of ketoprofen with the schema of administration consisting in the administration of one intravenous dose of 100 ml of NaCl 0.9% following 6 oral intakes of a placebo pill every 12h (a total regimen of 6 doses of placebo of NSAID every 12 h for 72h)
Study: NCT06716216
Drug: Drug: 5 mg BGM0504 Administered SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental: 5 mg BGM0504 5 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week.
Study: NCT06716216
Drug: Drug:10 mg BGM0504 Administered SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental: 10 mg BGM0504 10 mg BGM0504 administered SC once a week.
Study: NCT06719362
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX will be given as standard of care on 14 day cycles. Subjects will receive oxaliplatin 85 mg/m2 IV on Day 1, leucovorin 400 mg/m2 IV on Day 1, fluorouracil 400 mg/m2 IV push on Day 1, and fluorouracil 1,200 mg/m2 IV continuous infusion on Days 1-2 every 14 days for up to 9 cycles.
Study: NCT06719128
Drug: Olomorasib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT06705764
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1.91 ml subcutaneous every 4 weeks. Randomized Control Trial 90 days with Tezepelumab/ Matching Placebo dosing on Day 0, Day 30 and Day 60.
Study: NCT06705595
Drug: Tracheo-Spray
Normalized name: bovine type II collagen (tracheal cartilage)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 2 ml of 10% lidocaine delivered via a Tracheo-Spray device to the tracheal mucosa before anesthesia induction.
Study: NCT06733350
Drug: Therapeutic Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given via injection, gel, lotion, or transdermal patch
Study: NCT06733038
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg/sqm iv over 2 hours day 1
Study: NCT06733038
Drug: Fluorouracil (5-FU)
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3200 mg/sqm 48 h-continuous infusion, starting on day 1
Study: NCT05293912
Drug: SG2501
Approvals — FDA: no, EMA: no, PMDA: no
Description: During study treatment, subjects will receive SG2501 treatment via IV infusion once every week at doses of: 0.01, 0.03, 0.1, 0.3, 1, 2, 4 and 6mg/kg.
Study: NCT06721962
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low dose cyclophosphamide conditioning.
Study: NCT05289947
Drug: MLC1501
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powdered extract of Radix astragali, Rhizoma chuanxiong, Radix angelica sinensis, Radix polygala
Study: NCT06209281
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administer to eyes
Study: NCT06736717
Drug: NALIRIFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy regimen of nanoliposomal irinotecan, oxaliplatin, fluorouracil \[5-FU\], and leucovorin.~Intravenously on Day 1 of each 14-day cycle.
Study: NCT06740019
Drug: JMKX000197
Approvals — FDA: no, EMA: no, PMDA: no
Description: for pleural perfusion
Study: NCT06738758
Drug: PCSK9 inhibitor
Normalized name: PCSK9 inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient used PCSK9 inhibitor (with or without statins ± Ezetimibe/Hybutimibe) in the early hospitalization, and patients continually prescribed or stopped PCSK9 inhibitors treatment during the follow-up visit, which depend on physician's clinical decision and patient preference. PCSK9 inhibitors include Evolocumab, Alirocumab, Tafolecimab, Recaticimab, and Inclisiran, among others.